Last reviewed · How we verify
glycopyrrolate, 4.0%
At a glance
| Generic name | glycopyrrolate, 4.0% |
|---|---|
| Also known as | DRM04B |
| Sponsor | Journey Medical Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis (PHASE2)
- Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025) (PHASE3)
- Assessing the Effectiveness of Midazolam Premedication (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glycopyrrolate, 4.0% CI brief — competitive landscape report
- glycopyrrolate, 4.0% updates RSS · CI watch RSS
- Journey Medical Corporation portfolio CI